cardiac amyloidosis

PALO ALTO, Calif., August 30, 2026 BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of...

Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...

PALO ALTO, Calif., Aug. 26, 2026 BridgeBio Pharma, Inc. has announced that the first participant has been dosed in...

BERLIN, Germany / WHIPPANY, N.J., May 7, 2026 Bayer announced positive topline results from the pivotal Phase III REVEAL...

CAMBRIDGE, Mass., April 8, 2026 Anumana, Inc. has received U.S. FDA clearance for its ECG-AI™ algorithm designed to detect...